NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$147.78M | -$158.56M | -$141.22M | $10.66M | -$29.51M |
| Capital expenditure | - | - | - | - | - |
| Investing cash flow | -$174.92M | -$62.85M | -$24.00K | -$221.00K | -$24.00K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
NewAmsterdam Pharma Company N.V. reported operating cash flow of -$147.78M for fiscal year 2025. That is up 6.8% from -$158.56M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$29.51M (FY 2021) to -$147.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $29.52M | $659.51M | $8.91M | $391.90M | $84.70M |